2016
Characteristics of youth with type 1 diabetes (T1D) with and without a parent with T1D in the T1D exchange clinic registry
Fox LA, Mubasher M, Wolfsdorf JI, Buckingham BA, Peters AL, Tamborlane WV, Schatz DA, Maahs DM, Miller KM, Beck RW, Network F. Characteristics of youth with type 1 diabetes (T1D) with and without a parent with T1D in the T1D exchange clinic registry. Journal Of Diabetes 2016, 8: 834-838. PMID: 26663683, DOI: 10.1111/1753-0407.12363.Peer-Reviewed Original ResearchConceptsType 1 diabetesDiabetic ketoacidosisT1D Exchange Clinic RegistryInsulin pump therapyT1D Exchange RegistryContinuous glucose monitoringAcute complicationsGlycemic controlSevere hypoglycemiaClinic registryPump therapyPresent studyDiabetes managementT1D.T1DStudy participantsGlucose monitoringLinear mixed modelsDiabetesRegistryCharacteristics of youthChildrenAdolescentsMixed modelsStatistical comparison
2015
Moving toward the ideal insulin for insulin pumps
Cengiz E, Bode B, Van Name M, Tamborlane WV. Moving toward the ideal insulin for insulin pumps. Expert Review Of Medical Devices 2015, 13: 57-69. PMID: 26560137, DOI: 10.1586/17434440.2016.1109442.Peer-Reviewed Original ResearchConceptsTime-action profileGlycemic controlInsulin formulationsRapid-acting insulin analoguesPhysiologic insulin profilesOptimal glycemic controlInsulin pump therapyNew insulin formulationsQuality of lifeContinuous glucose monitoringRegular insulinPump therapyInsulin profilesPharmacological advancesDiabetes managementInsulin analoguesInsulin absorptionInsulin pumpGlucose monitoringInsulin deliveryPump systemTherapyInsulinDelivery methodsDiabetesUse of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries
Sherr JL, Hermann JM, Campbell F, Foster NC, Hofer SE, Allgrove J, Maahs DM, Kapellen TM, Holman N, Tamborlane WV, Holl RW, Beck RW, Warner JT, for the T1D Exchange Clinic Network, the DPV Initiative, and the National Paediatric Diabetes Audit and the Royal College of Paediatrics and Child Health registries. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia 2015, 59: 87-91. PMID: 26546085, DOI: 10.1007/s00125-015-3790-6.Peer-Reviewed Original ResearchConceptsType 1 diabetesPump useMetabolic controlFrequency of insulinLower mean HbA1cProspective Diabetes FollowNational Paediatric Diabetes AuditSimilar clinical characteristicsInsulin pump therapyEthnic minority statusMulticentre registryMean HbA1cClinical characteristicsPediatric registryPediatric patientsT1D ExchangePooled analysisPump therapyDiabetes AuditAims/RegistryInsulin pumpDiabetesInsulin deliveryT1DX
2013
Effectiveness of Early Intensive Therapy on β-Cell Preservation in Type 1 Diabetes
Buckingham B, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA, Bremer AA, Slover R, Tamborlane WV, . Effectiveness of Early Intensive Therapy on β-Cell Preservation in Type 1 Diabetes. Diabetes Care 2013, 36: 4030-4035. PMID: 24130350, PMCID: PMC3836135, DOI: 10.2337/dc13-1074.Peer-Reviewed Original ResearchConceptsUsual care groupC-peptide concentrationsType 1 diabetesΒ-cell functionHybrid closed-loop controlSAP therapyPump therapyContinuous glucose monitorNew-onset type 1 diabetesPeak C-peptide concentrationMixed-meal tolerance testSensor-augmented pump therapyEarly intensive therapyΒ-cell preservationUsual care participantsDays of diagnosisC-peptide areaMultiple daily injectionsInsulin pump therapyDays/weekMean glucose concentrationMedian durationIntensive therapyPrimary outcomeDaily injectionsRace, Socioeconomic Status, and Treatment Center Are Associated with Insulin Pump Therapy in Youth in the First Year Following Diagnosis of Type 1 Diabetes
Lin MH, Connor CG, Ruedy KJ, Beck RW, Kollman C, Buckingham B, Redondo MJ, Schatz D, Haro H, Lee JM, Tamborlane WV, Wood F. Race, Socioeconomic Status, and Treatment Center Are Associated with Insulin Pump Therapy in Youth in the First Year Following Diagnosis of Type 1 Diabetes. Diabetes Technology & Therapeutics 2013, 15: 929-934. PMID: 23869706, PMCID: PMC3817890, DOI: 10.1089/dia.2013.0132.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsBlood GlucoseBlood Glucose Self-MonitoringChildChild, PreschoolDiabetes Mellitus, Type 1Diabetic KetoacidosisFemaleHealth Services AccessibilityHealthcare DisparitiesHumansHypoglycemic AgentsInfantInfusion Pumps, ImplantableInsulinInsulin Infusion SystemsMaleMedically UninsuredSocioeconomic FactorsUnited StatesConceptsNon-Hispanic white raceInsulin pump therapyPump therapyPump useWhite raceFirst yearSocioeconomic statusPediatric diabetes centersTime of diagnosisType 1 diabetesPercent of participantsHigher socioeconomic statusAnnual household incomeNew onsetDiabetes CenterCox regressionT1D diagnosisPrivate health insuranceFollowing DiagnosisNumber of childrenTreatment centersMultivariate analysisTherapyType 1Early use
2011
A Bridge to Insulin Pump Therapy: Twice-Daily Regimen with NPH and Detemir Insulins During Initial Treatment of Youth with Type 1 Diabetes Mellitus
Cengiz E, Sherr JL, Erkin-Cakmak A, Weinzimer SA, Burke EN, Sikes KA, Urban AD, Tamborlane WV. A Bridge to Insulin Pump Therapy: Twice-Daily Regimen with NPH and Detemir Insulins During Initial Treatment of Youth with Type 1 Diabetes Mellitus. Endocrine Practice 2011, 17: 862-866. PMID: 21550949, DOI: 10.4158/ep11031.or.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildCohort StudiesDiabetes Mellitus, Type 1Diabetic KetoacidosisDrug Administration ScheduleDrug MonitoringDrug Therapy, CombinationFemaleFollow-Up StudiesGlycated HemoglobinHospitals, PediatricHospitals, UniversityHumansHypoglycemiaHypoglycemic AgentsInjections, SubcutaneousInsulin DetemirInsulin Infusion SystemsInsulin, IsophaneInsulin, Long-ActingInsulin, Short-ActingMaleConceptsRapid-acting insulin analoguesInsulin detemirNPH insulinYounger patientsA1c levelsInitial treatmentInsulin dosesNew-onset type 1 diabetes mellitusInsulin analoguesBasal/bolus insulinTotal daily insulin dosesType 1 diabetes mellitusInsulin injection treatmentPump-treated patientsDaily insulin dosesHemoglobin A1c levelsTwice daily regimenEffective initial treatmentSevere hypoglycemic eventsNew-onset T1DMInsulin pump therapyDetemir insulinDaily regimenInsulin regimenDiabetes mellitusNew-generation diabetes management: glucose sensor-augmented insulin pump therapy
Cengiz E, Sherr JL, Weinzimer SA, Tamborlane WV. New-generation diabetes management: glucose sensor-augmented insulin pump therapy. Expert Review Of Medical Devices 2011, 8: 449-458. PMID: 21728731, PMCID: PMC3177536, DOI: 10.1586/erd.11.22.Peer-Reviewed Original ResearchConceptsSensor-augmented insulinSensor-augmented insulin pump therapyCommon chronic disorderInsulin pump therapyContinuous subcutaneous insulin infusion systemsInsulin infusion systemField of diabetesPump therapyGlucose variabilityChronic disordersChallenging diseaseContinuous glucose monitorDelivery of insulinDiabetes managementInfusion systemTherapyInsulin deliveryTechnologic advancesInsulin
2010
STAR 3 Randomized Controlled Trial to Compare Sensor-Augmented Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 1 Diabetes: Research Design, Methods, and Baseline Characteristics of Enrolled Subjects
Davis SN, Horton ES, Battelino T, Rubin RR, Schulman KA, Tamborlane WV. STAR 3 Randomized Controlled Trial to Compare Sensor-Augmented Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 1 Diabetes: Research Design, Methods, and Baseline Characteristics of Enrolled Subjects. Diabetes Technology & Therapeutics 2010, 12: 249-255. PMID: 20210562, PMCID: PMC2883476, DOI: 10.1089/dia.2009.0145.Peer-Reviewed Original ResearchConceptsMultiple daily injectionsContinuous subcutaneous insulin infusionType 1 diabetesPercentage of subjectsPump therapyEnd pointBaseline characteristicsDaily injectionsKey safety end pointsType 1Sensor-Augmented Pump TherapyReal-time continuous glucose monitoringSensor-Augmented Insulin Pump TherapyNormal glycemic rangeTertiary end pointPrimary end pointSafety end pointSecondary end pointsInsulin pump therapySubcutaneous insulin infusionYears of treatmentContinuous glucose monitoringMDI cohortSevere hypoglycemiaClinical outcomes
2008
Effect of Age of Infusion Site and Type of Rapid-Acting Analog on Pharmacodynamic Parameters of Insulin Boluses in Youth With Type 1 Diabetes Receiving Insulin Pump Therapy
Swan KL, Dziura JD, Steil GM, Voskanyan GR, Sikes KA, Steffen AT, Martin ML, Tamborlane WV, Weinzimer SA. Effect of Age of Infusion Site and Type of Rapid-Acting Analog on Pharmacodynamic Parameters of Insulin Boluses in Youth With Type 1 Diabetes Receiving Insulin Pump Therapy. Diabetes Care 2008, 32: 240-244. PMID: 19017777, PMCID: PMC2628686, DOI: 10.2337/dc08-0595.Peer-Reviewed Original ResearchConceptsInsulin pump therapyGlucose infusion rateType 1 diabetesDay 1Day 4Pump therapyInsulin aspartPharmacodynamic parametersInsulin actionInsulin bolusRapid acting analogsEuglycemic clamp procedureExogenous glucose infusionGIR curveEffect of agePharmacodynamic measuresPharmacodynamic characteristicsClamp procedureInfusion siteGlucose infusionInfusion rateInsulin analoguesType 1AspartOverall insulin actionPast, present, and future of insulin pump therapy: better shot at diabetes control
Sherr J, Tamborlane WV. Past, present, and future of insulin pump therapy: better shot at diabetes control. Annals Of Global Health 2008, 75: 352-361. PMID: 18729180, PMCID: PMC2562271, DOI: 10.1002/msj.20055.Peer-Reviewed Original ResearchConceptsPump therapyDiabetes controlContinuous subcutaneous insulin infusion (CSII) therapySubcutaneous insulin infusion therapyContinuous subcutaneous insulin infusionInsulin pump therapyInsulin infusion therapySubcutaneous insulin infusionType 1 diabetesComplications TrialInfusion therapyInsulin infusionIntensive treatmentPump useTherapyArtificial pancreasContinuous glucose sensorsDelivery systemFindingsSelection criteriaPatientsDiabetesInfusionPancreasNew findings
2007
Effect of Puberty on the Pharmacodynamic and Pharmacokinetic Properties of Insulin Pump Therapy in Youth With Type 1 Diabetes
Swan KL, Weinzimer SA, Dziura JD, Steil GM, Voskanyan GR, Steffen AT, Martin ML, Tamborlane WV. Effect of Puberty on the Pharmacodynamic and Pharmacokinetic Properties of Insulin Pump Therapy in Youth With Type 1 Diabetes. Diabetes Care 2007, 31: 44-46. PMID: 17909083, DOI: 10.2337/dc07-0737.Peer-Reviewed Original Research
2006
Continuous subcutaneous insulin infusion (CSII) in children with type 1 diabetes
Tamborlane WV, Sikes KA, Steffen AT, Weinzimer SA. Continuous subcutaneous insulin infusion (CSII) in children with type 1 diabetes. Diabetes Research And Clinical Practice 2006, 74: s112-s115. PMID: 17182301, DOI: 10.1016/s0168-8227(06)70011-0.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionSubcutaneous insulin infusionType 1 diabetesInsulin infusionEfficacy of CSIIExcessive weight gainInsulin pump therapyNew insulin analoguesQuality of lifePediatric patientsSevere hypoglycemiaHemoglobin levelsPump therapyTreatment optionsClinical studiesInsulin analoguesWeight gainDiabetesInfusionChildrenRecent studiesSafetyHypoglycemiaPatientsTherapyThe renaissance of insulin pump treatment in childhood type 1 diabetes
Tamborlane WV, Swan K, Sikes KA, Steffen AT, Weinzimer SA. The renaissance of insulin pump treatment in childhood type 1 diabetes. Reviews In Endocrine And Metabolic Disorders 2006, 7: 205-213. PMID: 17160722, DOI: 10.1007/s11154-006-9018-9.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionQuality of lifePump therapyEfficacy of CSIINormal blood sugar levelsType 1 diabetes mellitusChildhood type 1 diabetesRisk of hypoglycemiaInsulin pump therapyBlood sugar levelsSubcutaneous insulin infusionType 1 diabetesNew insulin analoguesTreatment of childrenMacrovascular complicationsDiabetes mellitusPediatric patientsSevere hypoglycemiaHemoglobin levelsPatient selectionTreatment optionsInsulin infusionClinical studiesAge of childrenInsulin analogues
2005
Contrasting Challenges of Insulin Pump Therapy in a Toddler and Adolescent With Type 1 Diabetes
Doyle Boland EA, Steffen AT, Tamborlane WV. Contrasting Challenges of Insulin Pump Therapy in a Toddler and Adolescent With Type 1 Diabetes. The Science Of Diabetes Self-Management And Care 2005, 31: 584-590. PMID: 16100334, DOI: 10.1177/0145721705278888.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionType 1 diabetesGlycemic controlCSII therapyHypoglycemic episodesInsulin bolus dosesHemoglobin A1c levelsPediatric diabetes clinicSevere hypoglycemic episodesInsulin pump therapySubcutaneous insulin infusionYears of ageAge 13 yearsA1c levelsCatheter siteDiabetes clinicBolus dosesPump therapyDaily injectionsIdeal therapyInsulin infusionInsulin injectionsPostprandial hyperglycemiaFood intakePump use
2004
Rediscovery of insulin pump treatment of childhood type 1 diabetes.
Weinzimer SA, Doyle EA, Steffen AT, Sikes KA, Tamborlane WV. Rediscovery of insulin pump treatment of childhood type 1 diabetes. Minerva Medica 2004, 95: 85-92. PMID: 15272243.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionInsulin pump therapyQuality of lifeSevere hypoglycemiaPump therapyLong-term microvascular complicationsEfficacy of CSIIType 1 diabetes mellitusWeight gainChildhood type 1 diabetesExcessive weight gainBasal infusion rateSubcutaneous insulin infusionType 1 diabetesNew insulin analoguesTreatment of childrenContinuous glucose monitoringMicrovascular complicationsDiabetes mellitusPediatric patientsHemoglobin levelsNocturnal hypoglycemiaTreatment optionsNormal glycemiaInsulin infusion
2003
Insulin Pump Therapy in Childhood Diabetes Mellitus
Tamborlane WV, Fredrickson LP, Ahern JH. Insulin Pump Therapy in Childhood Diabetes Mellitus. Treatments In Endocrinology 2003, 2: 11-21. PMID: 15871551, DOI: 10.2165/00024677-200302010-00002.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionSevere hypoglycemiaEffectiveness of CSIIType 1 diabetes mellitusRapid-acting insulin analoguesDevelopment of ketoacidosisNear-normal glycemiaOvernight glycemic controlProgrammable basal ratesExcessive weight gainSelection of patientsExercise-induced hypoglycemiaInitiation of treatmentInsulin pump therapySubcutaneous insulin infusionBlood glucose levelsTiming of mealsQuality of lifeContinuous glucose monitoringCare of childrenBolus capabilitiesPediatrie patientsDiabetic ketoacidosisVascular complicationsDiabetes mellitus